After an FDA reviewer found no cause for alarm in pivotal data for Merck’s newest allergy drug, the fate of the company’s oral treatment for ragweed pollen allergies lies in the hands of agency advisers and choosey payers.

…read more

Source: Merck readies its latest allergy pill for FDA scrutiny and an uphill battle